Entrectinib (ENB) is an orally bioavailable small-molecule tyrosine kinase inhibitor initially developed for treating NTRK fusion-positive solid tumors and ROS1-positive non-small cell lung cancer (NSCLC). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.